ated with the risk of the development of CKD [3] , and alteration, both in lipid levels and structure, leads to metabolic changes that accompany the loss of renal function [4] . HDL maturation is impaired as a consequence of decreased activity of lecithin cholesterol acyl transferase [5] , which esterifies cholesterol allowing the expansion of HDL into spherical HDL, an isoform that carries the antioxidant enzymes arylhydrocarbon hydrolase and paraoxinase 1 (PON1) [6] . The lack of maturation results in a disproportionate fraction of residual HDL to remain in the discoid pre β subclass, a form that does not bind to PON1 and is an ineffective antioxidant [7] . Thus, HDL in dialysis patients has reduced the ability to protect low-density lipoprotein (LDL) from oxidation [7] .
TG-rich lipoproteins, very-LDL (VLDL) and chylomicrons (CM) exhibit a prolonged half-life [8] as a consequence of resistance of the particles to the action of lipoprotein lipase (LPL). This comes as a result of increased concentrations of the LPL inhibitory apolipoproteins C III and apolipoprotein C I relative to the LPL activating apolipoprotein C II. The increased resonance time of VLDL and CM remnant particles further increases their risk of oxidation [4] . The consequence of this is accumulation of increased fraction of LDL that is oxidized [9] , although it is uncertain whether oxidized LDL contributes to adverse outcomes in this population [10] .
Thus, the levels of lipoproteins in dialysis patients may not provide the same expected effect on outcomes as anticipated based upon effects observed in patients with unimpaired renal function. Indeed, the total cholesterol level [11, 12] is inversely associated with mortality in dialysis patients suggesting either that cholesterol may have limited ability to adversely affect outcomes, or that other processes that are not associated with lipid levels have a dominant effect on the observed increase in all-cause and cardiovascular outcomes, perhaps overwhelming the effect mediated by lipoproteins.
Statins
Several clinical trials exploring the effect of lipid lowering therapy on cardiovascular outcomes and on allcause mortality and morbidity [13] [14] [15] have been completed. The 4D trial was a prospective randomized study of the effect of atorvastatin on cardiovascular mortality, myocardial infarction and stroke in 1,255 dialysis patients with type 2 diabetes [13] . The effect size on primary outcomes, which was a composite of death from cardiac causes, nonfatal myocardial infarction and stroke was small, approximately 13% and not statistically significant. There was no effect of treatment on inflammation measured as C-reactive protein (CRP). A secondary end point, all cardiac events combined, was significant (RR 0.82 (0.68-0.99); p = 0.03). A second trial examined the effect of rosuvastatin on the primary end point: time to a major cardiovascular event, defined as a nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The effect on these outcomes was not significant despite a significant reduction in LDL cholesterol and CRP [14] . The largest study conducted to date is the SHARP study, which evaluated the effect of simvastatin plus ezetimibe on 3,023 dialysis patients and on 6,247 CKD patients who were not on dialysis [15] . The primary outcomes did not include mortality, but were non-fatal myocardial infarction or any cardiac death, any stroke or any arterial revascularization excluding dialysis access procedures. There was a significant reduction in risk by 17% in the treatment group, but the effect was completely confined to the patients who were not on dialysis. Overall, there was no effect on mortality in the trial (RR 1.02 (0.94-1.11)) and no effect on the selected outcomes among dialysis patients (RR 0.90 (0.75-1.08)). Thus, it appears that while treatment with a statin does reduce LDL cholesterol levels and in some instances CRP as well, there is no effect on mortality or on cardiovascular outcomes that are statistically significant among patients on hemodialysis. Conversely, the anticipated effects on cardiovascular outcomes appear to be preserved among patients with CKD who do not yet need renal replacement therapy.
Fibric Acid and Niacin
Fenofibrate has been observed to increase serum creatinine concentrations in patients with CKD, raising safety concerns [16] . Nevertheless, a randomized controlled trial on the use of fenofibrate in a group of patients with type 2 diabetes and CKD (estimated glomerular filtration rate, eGFR 30-59, 60-89 and ≥ 90 ml/min/1.73 m 2 ) showed efficacy (composite of cardiovascular death, myocardial infarction, stroke and coronary/carotid revascularization) that appeared to be confined to the group of patients with eGFR 30-59 [17] . No adverse effect of fenofibrate on renal function was reported. Indeed, despite an initial increase in creatinine, long-term treatment with fenofibrate reduced the rate of loss of renal function in patients with type 2 diabetes [18] . It is unclear whether there is therapeutic benefit in the use of fenofibrate in dialysis patients. Use of niacin among dialysis patients has been directed at reduction in serum phosphorous and, with the exception of increased flushing, appears to be safe [19] .
Effect of Inflammation
Although lipid levels and structures among patients requiring dialysis suggest that the lipid-lowering therapy should be effective in this population with a 30-fold increase in cardiovascular events, reduction in risk is not effected in prospective clinical trials. One explanation for this outcome is that the increased risk acquired as renal function fails is mediated by a process other than the effect of lipids so that any treatment effect is obscured by the acquisition of an additional risk contributor. Inflammation provides such a mechanism [20] . Indeed, in a post hoc analysis of the 4D trial, 'wasting' defined as hypoalbuminemia, low serum creatinine and an elevated CRP resulted in the greatest risk for all-cause mortality and for combined cardiovascular events independently of the cholesterol level [21] . Among dialysis patients, mortality is inversely associated with cholesterol [11] , although this association is reversed after adjustment for CRP [12] . A similar disassociation of cholesterol and cardiovascular outcomes in patients with CKD mediated by the presence of inflammation was demonstrated in the African-American Study of Kidney Disease and Hypertension study, where among this cohort of pre dialysis patients with eGFR between 20 and 65 ml/min/1.73 m 2 , an increasing hazards ratio for cardiovascular outcomes was observed among the patients without inflammation, while this relationship was obscured among patients with inflammation [22] . Thus, the acquisition of a cardiovascular and mortality risk factor that is independent of lipid levels and most likely contributing to significantly more risk for adverse outcomes would tend to obscure any potential benefit of the lipid-lowering therapy.
Lipid-Lowering Therapy in the Nephrotic Syndrome
The nephrotic syndrome is associated with significant increases in blood lipid levels as a consequence of proteinuria [23] . Hyperlipidemia can be reduced by decreasing urinary albumin loss [24] and is a consequence of increased synthesis of LDL, lipoprotein (a) [25, 26] and decreased lipolysis of TG-rich lipoproteins as a consequence of retention of fatty acid enriched albumin by selective sieving by damaged podocytes, which in turn stimulates the production of circulating angiopoeitin-like 4 protein [27] , an inhibitor of LPL.
Statins are effective in reducing lipid levels in nephrotic patients [28] , but no long-term hard outcome studies are available to access treatment effects. In addition to increased LDL synthesis, defective removal as a consequence of increased levels of proprotein convertase subtilisin/kexin type 9 has been described to be increased as a consequence of increased hepatic synthesis. Inhibition of this protein presents another potential therapeutic target for control of hyperlipidemia in this syndrome [29] .
